55826-72-7

Upstream product

• 100-51-6 benzyl alcohol 
• 6082-66-2 3,4,6-trichloropyridazine 

Downstream Products

• 1425512-20-4 3,4-bis(benzyloxy)-6-{[3,5-bis(trifluoromethyl)phenyl]-methyl}pyridazine 
• 1425512-24-8 ethyl 5,6-bis(benzyloxy)pyridazine-3-carboxylate 
• 1425511-66-5 3,4-bis(benzyloxy)-6-((trimethylsilyl)ethynyl)pyridazine 
• 1425512-39-5 3,4-bis(benzyloxy)-6-ethenylpyridazine 
• 1425511-85-8 6-benzyl-3,4-bis(benzyloxy)pyridazine 
• 1425511-87-0 3,4-bis(benzyloxy)-6-(1-phenylethenyl)pyridazine 
• 1425512-21-5 4-{2-[5,6-bis(benzyloxy)pyridazin-3-yl]ethynyl}oxan-4-ol 
• 1425512-22-6 3,4-bis(benzyloxy)-6-[2-(3,6-dihydro-2H-pyran-4-yl)ethynyl]pyridazine 
• 1425512-23-7 5,6-bis(benzyloxy)-N-[(4-fluorophenyl)methyl]-N-methylpyridazin-3-amine 
• 1425512-25-9 5,6-bis(benzyloxy)pyridazine-3-carbaldehyde 
• 1425512-26-0 (5,6-bis(benzyloxy)pyridazin-3-yl)(cyclopropyl)methanol 
• 1425512-27-1 3,4-bis(benzyloxy)-6-(cyclopropylidenemethyl)pyridazine 
• 1425512-34-0 3,4-bis(benzyloxy)-6-[(E)-2-[3,4-bis(trifluoromethyl)phenyl]-ethenyl]pyridazine 
• 1425512-35-1 3,4-bis(benzyloxy)-6-((3-methyl-4-(trifluoromethyl)phenyl)-ethynyl)pyridazine 

Relevant academic research and scientific papers

Synthesis and biochemical evaluation of lid-open D-amino acid oxidase inhibitors

Most of the known inhibitors of D-amino acid oxidase (DAAO) are small polar molecules recognized by the active site of the enzyme. More recently a new class of DAAO inhibitors has been disclosed that interacts with loop 218?224 at the top of the binding pocket. These compounds have a significantly larger size and more beneficial physicochemical properties than most reported DAAO inhibitors, however, their structure-activity relationship is poorly explored. Here we report the synthesis and evaluation of this type of DAAO inhibitors that open the lid over the active site of DAAO. In order to collect relevant SAR data we varied two distinct parts of the inhibitors. A systematic variation of the pendant aromatic substituents according to the Topliss scheme resulted in DAAO inhibitors with low nanomolar activity. The activity showed low sensitivity to the substituents investigated. The variation of the linker connecting the pendant aromatic moiety and the acidic headgroup revealed that the interactions of the linker with the enzyme were crucial for achieving significant inhibitory activity. Structures and activities were analyzed based on available X-ray structures of the complexes. Our findings might support the design of drug-like DAAO inhibitors with advantageous physicochemical properties and ADME profile.

Synthesis and preliminary evaluation of 4-hydroxy-6-(3-[11C]methoxyphenethyl)pyridazin-3(2H)-one, a 11C-labeled D-amino acid oxidase (DAAO) inhibitor for PET imaging

Selective DAAO inhibitors have demonstrated promising therapeutic effects in clinical studies, including clinically alleviating symptoms of schizophrenic patients and ameliorating cognitive function in Alzheimer's patients with early phase. Herein we repo

PYRIDAZINONES AS DAAO ENZYME INHIBITORS

The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1 and R2 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.

PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS

The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1 and R2 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.

NOVEL COMPOUNDS

The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1 and R2 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy